logo
​Drinking to death: on illicit liquor cases

​Drinking to death: on illicit liquor cases

The Hindu16-05-2025
Often described in media reports as 'hooch tragedies' or 'spurious liquor cases', the recurring incidents of illicit alcohol poisoning across India — most recently near Amritsar, Punjab, which claimed at least 23 lives — follow a grimly familiar pattern of poverty, greed, and regulatory failure. Each tragedy is eerily similar to the previous one, be it in terms of the socio-economic profile of the victims or the motivation of the perpetrators. The victims are typically poor, daily wage earners, seeking respite from the harsh realities of everyday drudgery. They are drawn by the lure of cheap alcohol, a vulnerability exploited by bootleggers, who are at the fag end of a long supply chain. These illicit brews often involve dangerous shortcuts, from incorporating toxic substances such as dead scorpions to diluting industrial methanol, a poisonous chemical that is deceptively similar to consumable ethanol. Methanol, easily pilfered and inexpensive, becomes a deadly profit source for bootleggers who may misjudge dilution ratios, leading to fatal consequences. The nexus among bootleggers, the police, and lower-level politicians is often apparent. While police negligence in Punjab has led to suspensions, these events are more about organised methanol theft in which the bootlegger is only the last mile operator. Methanol is not a drink; it is industrial alcohol, an intermediary in the petrochemical industry with extensive downstream use, and is, therefore, not illicit, except as an ingredient in hooch. It is categorised as a Class B poison in many States, but is cheaper than the liquor made biologically, mostly from molasses. After paying for the pilferage from authorised methanol dealers, bootleggers can still make a handsome profit.
Legal proceedings in illicit liquor cases often involve murder and attempted murder charges, besides those under prohibition laws. Yet convictions, as seen in the 2015 Malvani case, can be elusive. A court acquitted 10 of the 14 accused after nine years. None was found guilty of violating the Poison Act. Since methanol production and delivery are inter-State affairs, there is a case for a central framework on methanol transport for preventing such pilferage as well as stringent State regulation. The Poison Act may add teeth to the prosecution's case. But what is more important is to ensure that the lawmaker-enforcer dyad is incorruptible so that illegal methanol distribution is impossible. Eventually though, it is the sorry economic, social and educational situation of victims that creates a market for unscrupulous agents to make money. This can only be eradicated by tackling poverty, social inequality, and the lack of access to education alongside systemic corruption within law enforcement.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US stocks tend to gain around Fed's Jackson Hole summer conference, analysis shows
US stocks tend to gain around Fed's Jackson Hole summer conference, analysis shows

Yahoo

time18 minutes ago

  • Yahoo

US stocks tend to gain around Fed's Jackson Hole summer conference, analysis shows

By Lewis Krauskopf NEW YORK (Reuters) -U.S. stocks have tended to fare well around the Federal Reserve's Jackson Hole gathering in August, according to a historical analysis from DataTrek Research, although the market has seen sizable moves in both directions in recent years. The Fed's annual Wyoming research conference is set for Thursday through Saturday, and Chair Jerome Powell's speech on Friday is expected to be the main event for markets. DataTrek looked at the benchmark S&P 500 in the five trading days before and after the Fed chair's speech since 2010. The index gained an average of 0.9% over the period, with the bulk after the speech. "This suggests that markets get incremental clarity from the chair's speech, which in turn boosts equity valuations," Nicholas Colas, DataTrek's co-founder, said in a research note. This year, the S&P 500 has slipped in the lead-up to the speech so far, Colas said in the note published early Tuesday. "This goes against the usual pattern, so we would not be surprised to see the index rally modestly through Thursday," he said. One notable exception to the trend was in 2022, when the index slumped 7.4% in the 10-day period. That year at Jackson Hole, Powell warned of slower growth as the Fed fought high inflation. The S&P 500 fell over 19% for the full year 2022 as the Fed raised interest rates. In 2023, the index gained 3.3% in the studied period. DataTrek noted the S&P 500 fell in 2013 and 2015 when Fed chairs Ben Bernanke and Janet Yellen did not attend the symposium. This year, investors are eager to see if Powell reinforces expectations of a central bank interest rate cut at its September 16-17 meeting. Recent weak labor market data bolstered those expectations. Fed Fund futures on Tuesday were pricing in an 84% chance of such a move, according to LSEG data.

Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma

Yahoo

time18 minutes ago

  • Yahoo

Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma

JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc.

6 Chiefs won't practice on Tuesday; Steve Spagnuolo weighs in
6 Chiefs won't practice on Tuesday; Steve Spagnuolo weighs in

Yahoo

time18 minutes ago

  • Yahoo

6 Chiefs won't practice on Tuesday; Steve Spagnuolo weighs in

Ahead of their practice at their home facility at the Truman Sports Complex on Tuesday, the Kansas City Chiefs listed six players who would not take the field due to injury or illness: linebacker Jack Cochrane (knee bruise), offensive lineman Ethan Driskell (appendectomy), safety Mike Edwards (hamstring), cornerback Nazeeh Johnson (shoulder), defensive tackle Omarr Norman-Lott (ankle) and wide receiver Jalen Royals (knee). Late Monday afternoon, Kansas City placed defensive end Felix Anudike-Uzomah on the Reserve/Injured list. Even though he is practicing, cornerback Kristian Fulton has yet to play in a preseason game as he recovers from offseason knee surgery. 'Well, the unknown is Kristian right now because we haven't had him out there,' said defensive coordinator Steve Spagnuolo. 'Jaylen [Watson] has missed some time, and now we've got [Johnson], who is a little dinged up. More than any group on the defense, that back end has to have a lot of continuity, and that comes with reps. So with a couple of different moving pieces, there's a little bit of concern there, so hopefully we can start to gel that together.' The Chiefs play their final game of the 2025 preseason against the Chicago Bears at home on Friday at 7:20 p.m. Arrowhead Time. Chiefs head coach Andy Reid has already confirmed that the starters will see playing time.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store